Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.
暂无分享，去创建一个
J. Burke | K. Kolibaba | J. Reeves | P. Zinzani | O. O’Connor | N. Ghosh | C. Cheah | J. Chavez | P. Ghia | E. Lech-Maranda | W. Jurczak | F. Samaniego | N. Fowler | J. Sharman | C. Tarella | L. Leslie | P. Patten | P. Sportelli | H. Miskin | M. Weiss